{"text": "TITLE:\n      Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)\nSUMMARY:\n      To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from\n      Diabetic Neuropathy.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes\n             with the pain beginning in the feet and present for at least 6 months.\n          -  May not be pregnant and agree to utilize medically acceptable and reliable means of\n             birth control during participation in the study.\n          -  Score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.\n        Exclusion Criteria:\n          -  History of substance abuse or dependence within the past year, excluding nicotine and\n             caffeine.\n          -  Serious or unstable cardiovascular, hepatic (acute liver injury such as hepatitis or\n             severe cirrhosis),kidney, respiratory, or blood disorder, seizure disorder, problems\n             with peripheral vascular disease, or other medical conditions or psychiatric\n             conditions that would hinder your participation or be likely to lead to\n             hospitalization during the course of the study.\n          -  Taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the\n             potential need to take during or within 5 days after discontinuation from the study.\n          -  Treatment with fluoxetine within 30 days of starting the study.\n          -  Unstable blood sugar control and uncontrolled or poorly controlled hypertension.\n", "cuis": "C0027796 C3714625 C0245561 C0241863 C1550655 C1578485 C1578486 C2360836 C2360838 C2360840 C1552616 C1706244 C0245561 C0030193 C1561542 C0011882 C0243161 C0013893 C0243161 C0031117 C1697744 C0564740 C0235025 C1263857 C0151313 C0011860 C0030193 C1552651 C0030193 C0016504 C0578010 C1561542 C0549206 C3858758 C0340978 C0700589 C2703065 C0947630 C1511326 C3539024 C4035101 C4050231 C0030193 C0243161 C1299544 C1397159 C0439857 C0086025 C0011546 C0028040 C0591863 C1561543 C0006644 C0202348 C2919093 C3668915 C3887460 C0007220 C0436125 C0497234 C0160390 C0019158 C0019159 C0011226 C0019163 C0019196 C0085293 C0814152 C0854496 C0443343 C1551395 C1552745 C0205054 C0014544 C0014547 C0018939 C0525045 C0455494 C0042497 C0087153 C2266627 C1546767 C0033213 C2081614 C1306232 C0085096 C0553983 C0162819 C0199686 C0011871 C3698278 C0012634 C3841442 C1548428 C3526598 C1442948 C0012634 C0019993 C3840878 C3841837 C3841838 C0947630 C0026457 C0452378 C0595265 C1629501 C3653412 C3653413 C0570756 C0947630 C0457454 C1444662 C0947630 C2222792 C0016365 C0068987 C0087111 C1533734 C3887704 C0746919 C0947630 C3842337 C0020538 C1963138 C1696708 C2748577 C0947663 C0443343 C0005768 C0229664 C0242209 C2239291 C0180112 C2911690 ", "concepts": "Neuropathic Pains, Neuropathic Pain, Duloxetine, Diabetic, Patient, Patient, Patient, Patient, Patient, Patient summary, summary duloxetine, pain, month Diabetic Neuropathy criteria, Eligibility Criteria Peripheral neuropathy NOS, HIV peripheral neuropathy, Other peripheral neuropathy, Motor peripheral neuropathy, axonal peripheral neuropathy, Sensory peripheral neuropathy, Type II diabetes, pain, Type pain, feet, Hand present, month pregnant, reliable, May birth controls, birth control, study Brief Pain Inventory, Brief Pain Inventory, Brief Pain Inventory (BPI), Score, pain Criteria History of substance abuse, Family history of substance abuse, dependence on, Codependence, dependency, nicotine, nicotinell, year Caffeine, Caffeine, caffeine, Caffeine cardiovascular, cardiovascular drug, cardiovascular exam, Pain;cardiovascular, liver injury, Hepatitis, Hepatitis, hepatitis D, hepatitis B, hepatitis C, e hepatitis, hepatitis g, h hepatitis, unstable, Serious, Serious, hepatic seizure disorder, focal seizure disorder, blood disorders, mood disorders, H/O: blood disorder, respirators, respirator, respirator, Respiratory, problem, problem:, severed PVD - Peripheral vascular disease, Other peripheral vascular diseases, peripheral vascular disease of skin, Peripheral vascular disease study, Diabetic peripheral vascular disease, Secondary peripheral vascular disease, condition, Other medical, Psychiatric, Psychiatric lead, condition hospitalization, Hospitalization 1, Hospitalization 3, Hospitalization 2, study monoamine oxidase inhibitors (MAOI), Monoamine oxidase inhibitor diet, Monoamine oxidase B inhibitor, Monoamine oxidase A inhibitor, Monoamine oxidase B inhibitors, Monoamine oxidase A inhibitors, Monoamine oxidase inhibitor allergy, study discontinuations, Discontinuation, study, OT potential fluoxetine, norfluoxetine, treatment, Treatment, treatment, No Treatment, study, 0 days hypertension, Hypertension, Prehypertensions, No hypertension, hypertensin, Unstable, blood, blood, sugar, sugars, controllers, Controlled "}
